Summary and conclusions A total of 764 patients with Hodgkin's disease treated with radiotherapy (RT) 
Introduction
The development of a second malignancy, particularly acute non-lymphoblastic leukaemia (ANLL), is increasingly being recognised as a complication of Hodgkin's disease. Though the association may occur by chance, it may be closely related to the type --of intensive treatment used. Direct evidence, however, is-lacking. Advances in radiotherapy (RT) and chemotherapy have led to significantly increased survival, and for many patients cure, at almost any stage of Hodgkin's disease. Nevertheless, this has not been achieved without some degree of treatment-induced morbidity, acute and delayed toxicity of antineoplastic treatment occurring in a broad range of tissues.'
Because of evidence in man of a potential carcinogenic effect of chemotherapy attention has been directed to studying risk factors for the development of new cancers. After the report from the National Cancer Institute in 19722 several studies confirmed that patients with Hodgkin's disease treated with extensive RT and intensive chemotherapy-namely, MOPP (mustine, vincristine, procarbazine, and prednisolone) and modified MOPP regimens-are at greatest risk of developing a second malignancy. 3 We decided to assess the incidence of second malignancies in groups of patients treated in various ways and with different *Presented in part at the 15th annual meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, [14] [15] reported times were as derived from the life-table plots. The median time from initial treatment in the whole series was 43 months (range 3-186 months).
Results Table II gives the incidences of second malignancy in patients treated with a single modality. The 236 patients given RT alone were reviewed after a median of 47 months (range 3-182 months). Involvedfield or mantle irradiation had been given to 119 (51%) of these patients, subtotal nodal RT to 85 (36%), and total nodal RT to 32 (13%'). None had developed ANLL within 10 years after initial treatment. During the same period, however, the incidence of solid tumours rose progressively to 14.9%. Over one-third of the patients were reviewed five years or more after first irradiation.
The 36 patients treated with chemotherapy alone were reviewed after a median of 24 months (range 3-85 months). Thirty-two of them were given regimens containing alkylating agents or procarbazine or both. No solid tumours occurred in this group, but one patient (incidence 555%) developed ANLL within three years after starting MABOP.
Of the 492 patients who received both RT and chemotherapy, 315 (64%) were given subtotal or total nodal irradiation. The extent of the fields irradiated was comparable in the different groups. Except for patients given RT plus MABOP, there was no appreciable difference between the subgroups in the timing of review after initial treatment (median 44 months) (see table III ). The subgroup given RT plus MABOP, however, were reviewed a median of 60 months after initial treatment, MABOP being the first combined drug regimen 217 to be used systematically in our institute. The overall incidence of solid tumours in the 492 patients rose progressively to 6-2% within 10 years after initial treatment (table III) . Such tumours, however, occurred only in subgroups given regimens containing an alkylating agent or procarbazine or both. The incidence of ANLL also increased with time (to 3-5% within 10 years) and again affected only patients treated with an alkylating agent or procarbazine. Of the patients given RT plus MOPP, for example, 5-4% developed leukaemia within five years after initial treatment. In contrast, of patients reviewed at comparable times after RT plus ABVD, none developed either a solid tumour or leukaemia. Table IV shows the initial treatments given to the nine patients who developed ANLL together with the timing of the diagnosis in relation to the beginning of initial treatment and the end of all treatment. Seven of the nine patients were given extensive radiotherapy plus combination chemotherapy. There was only one case of involved-field RT followed by prolonged administration of both mustine and procarbazine because of relapse. In five patients ANLL 
Discussion
The development of second malignancies in Hodgkin's disease was reported about 20 years ago,9 '0 but the possible role of treatment in inducing acute leukaemia and solid tumours was recognised muoh later. In most -recent reports second malignancies were diagnosed when the patients were in complete remission of Hodgkin's disease and off all treatment after receiving both intensive RT and combination chemotherapy. A multifactorial aetiology has been postulated-namely, impaired cellular immunity characterising advanced Hodgkin's disease, immunosuppressive effects of intensive treatment, and direct cellular effects of radiation and chemotherapy.' 311 In our series of 764 patients the development of solid tumours as a second disease occurred with an incidence of 7-30-within 10 years after initial treatment. Besides RT half of the patients had been given chemotherapy, which in all instances included an alkylating agent or procarbazine or both. Whether this heterologous group of tumours is related to treatment or represents a chance association, however, remains to be determined. Though therapeutic radiation may carry some increased risk of inducing a second tumour,'2 in our series only five out of 15 patients (two out of seven given RT alone) had a second solid malignancy documented in an irradiated area.
The most serious delayed complication noted in our series was acute leukaemia. Leukaemia occurred irrespective of whether combined-modality treatment had been given initially (two cases) or whether either modality had been given only as salvage treatment (six cases). This finding agrees with the observations of the National Cancer Institute3 and Stanford4 groups. Our results leave little doubt that this complication is related to treatment. In the 492 patients treated with irradiation BRITISH MEDICAL JOURNAL 26 JANUARY 1980 plus chemotherapy the incidence of leukaemia was 3 5% within 10 years after first treatment. Furthermore, 5-4% of patients treated with RT and MOPP developed leukaemia within five years, whereas no cases of leukaemia were documented after RT given either alone or with ABVD. The leukaemogenic potential in man of ionising radiation is well documented,"' and the incidence of post-irradiation leukaemia is known to be dose-related. So far as cytotoxic chemotherapy is concerned, many drugs have been incriminated in acute leukaemia, though alkylating agents predominate.'" All patients with documented acute leukaemia occurring in Hodgkin's disease had been given drugs containing an alkylating agent or procarbazine or both.'3 Procarbazine is a most potent leukaemogenic compound in experimental animals.'4 Although adriamycin and dacarbazine are carcinogenic in animals, '5 16 no cases of leukaemia or solid tumour occurred in our series after ABVD. Since patients given ABVD and other regimens were reviewed at comparable times after treatment we cannot explain the difference in carcinogenic effect between ABVD and combinations containing alkylating agents and procarbazine. Only relatively few patients were given ABVD, but we should have expected to find two patients with leukaemia from the number observed in the MOPP group. Hence, the drugs included in the ABVD regimen are probably weak carcinogens in man, at least when compared with alkylating agents and procarbazine.
How would recognising the risk of a second malignancy, particularly acute leukaemia, affect the treatment of Hodgkin's disease? Many patients with Hodgkin's disease are currently subjected to a combined-modality approach to improve the cure rate with extensive RT alone. From the 10-year results of the Stanford controlled trial'7 (RT alone v RT followed by six cycles of MOPP) patients with stages I, II, and III of the disease apparently obtain improved rates of remission and survival as a result of adjuvant MOPP.18 Both we'9 and the Yale group20 have shown that in advanced lymphoma (stages IIIA, IIIB, and IV) treated with combination chemotherapy followed by RT to sites of original disease 89-92%o of complete responders were alive at five years, the results being superior to those, usually obtained with MOPP chemotherapy alone. We do not infer that combined RT and chemotherapy should be regarded as an absolutely established method of treatment for all disease stages. Nevertheless, the combined-modality approach should clearly be tried further, at least in patients with unfavourable prognostic signs-for example, systemic symptoms, adenopathies above and below the diaphragm, and extranodal disease.
Since the results of this and other retrospective analyses show that extensive RT plus combination chemotherapy predisposes to the development of second malignancies, the benefit of such treatment must be weighed against its carcinogenic potential. Hence to reduce the risk of second malignancy possibly patients with disease confined to lymph nodes should be given RT alone as primary treatment, RT plus systemic chemotherapy being reserved for those who relapse. Patients who relapse after RT alone, however, are apparently at greater risk of developing acute leukaemia once chemotherapy has been given as salvage treatment. A second possibility would be to start combined treatment in patients with an unfavourable prognosis but limit the cycles of chemotherapy. Initial results of the South-west Oncology Group suggest that in patients with stages IIB, IIIA, and B of the disease three cycles of MOPP followed by total nodal RT yield excellent rates of remission and overall survival, which are comparable to those in patients given more than three cycles.21 Nevertheless, it is too soon to assess the difference in incidence ofsecond malignancies betweenthetwo chemotherapy groups. Since second malignancies have occurred only in cases treated with alkylating agents or procarbazine, a third possibility would be to utilise ABVD chemotherapy for patients requiring a combined-treatment modality. From prospective controlled trials'9 22 ABVD is apparently at least as effective as MOPP but devoid of carcinogenic activity. Our results confirm that adults and children with Hodgkin's disease are especially susceptible to second malignancies, particularly acute leukaemia, when treatment includes extensive RT and combination chemotherapy with alkylating agents or procarbazine. Thus until more conclusive data from clinical trials have established the absolute therapeutic value of RT plus combination chemotherapy this form of treatment should be reserved for patients with an unfavourable prognosis. To avoid the risk of treatment-induced malignancies probably chemotherapeutic regimens not containing alkylating agents and procarbazine should be used.
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ADDENDUM-Since this paper was submitted three more adult patients have developed a second malignancy after RT plus chemotherapy. Essential data are as follows: Case 1-This patient initially received three cycles of MOPP plus total nodal irradiation. The histopathological diagnosis from a subcutaneous nodule removed 16 months after beginning treatment was diffuse histiocytic lymphoma. Case 2-This patient was initially treated with mantle irradiation. At the time of first recurrence he was given MOPP for 12 cycles, and ANLL was detected 66 months after beginning RT. Case 3-This patient was initially treated with subtotal nodal irradiation plus vinblastine. Subsequently she was given corticosteroids and procarbazine for a suspicious recurrence. A sarcoma of the anterior thoracic wall was detected 76 months after beginning irradiation. ONE HUNDRED YEARS AGO The following story has recently reached the Statesman. "Dr Dumbleton, a young surgeon from St Bartholomew's Hospital, who only arrived in India to join the Indian Medical Service last March, was recently ordered to proceed to Peshawur. From Peshawur, Dr Dumbleton proceeded in medical charge of a draught en route to join the Kuram Valley force. Being but an indifferent horseman, he was much galled by his long ride. In addition, he suffered from a severe attack of fever, and, when on the march, his detachment met the 13th Bengal Lancers. The medical officer in charge of that regiment told Dr Dumbleton that he was in an utterly unfit state of health to proceed; he also provided him with a pair of drawers. Thus relieved, poor Dr Dumbleton managed to push on to Ali Kheyl. Here he went to a staff officer, who saw from his miserable appearance that he was quite unfit to go further, and he said that he would make arrangements for some other surgeon to go on with the detachment. The poor lad went to his tent, threw himself down in his clothes, and fell asleep. Early next morning, an officer of his detachment went to his tent and said, 'Come, Dumbleton, it is time to get up; we must be off.' Dr Dumbleton replied that he was utterly unfit to go on, as he was so ill, and that arrangements had been made for another surgeon to take his place; and the officer left him. Dr Dumbleton appears to have been a very sensitive young fellow, and he feared he should be accused of pretending to be worse than he really was. After a short time, the officer of his detachment returned, saying that no arrangement had been made for another surgeon to go with them, that they could not march without one, and that go he must. Dr Dumbleton replied that he could go no further, adding, 'By God, I am not shamming'; and the officer again left Dr Dumbleton in his tent. He had only gone a few yards when he heard the report of a pistol, and, rushing back to Dr Dumbleton's tent, he found the poor young fellow dead, with a revolver beside him." (British Medical Journal, 1880.) 
